With the removal of Relyvrio (sodium phenylbutyrate/taurursodiol) from the market, Amylyx Pharmaceuticals, Inc. will lose its sole commercial revenue stream and return its focus to pipeline development. The company announced on 4 April that it will withdraw Relyvrio from the US and Canada, where it is sold as Albrioza, immediately due to lack of efficacy for amyotrophic lateral sclerosis (ALS).
Amylyx Resets As A Clinical-Stage Company, Withdrawing Relyvrio
Workforce Will Be Cut By 70%
The ALS treatment Relyvrio was removed from the market as expected following a Phase III trial failure.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.